HSDT Stock Overview
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Helius Medical Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.44 |
| 52 Week High | US$14.44 |
| 52 Week Low | US$4.29 |
| Beta | 1.55 |
| 1 Month Change | -20.43% |
| 3 Month Change | -36.57% |
| 1 Year Change | -53.02% |
| 3 Year Change | -99.48% |
| 5 Year Change | -99.89% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Helius Medical Technologies: A Net-Net Meme Stock In The Making
Aug 23Helius Medical Technologies stock slides 51% after pricing $18M securities offering
Aug 05We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully
Aug 18
Helius Medical makes CEO, CFO appointments
Jun 15Helius Medical Technologies announces reverse stock split
Dec 31Helius Medical Technologies EPS beats by $0.01, beats on revenue
Nov 12Shareholder Returns
| HSDT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -13.1% | 1.6% | 1.0% |
| 1Y | -53.0% | -1.4% | 21.9% |
Price Volatility
| HSDT volatility | |
|---|---|
| HSDT Average Weekly Movement | 12.9% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Volatility Over Time: HSDT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 22 | Dane Andreeff | heliusmedical.com |
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company’s product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Helius Medical Technologies, Inc. Fundamentals Summary
| HSDT fundamental statistics | |
|---|---|
| Market cap | US$3.94m |
| Earnings (TTM) | -US$8.85m |
| Revenue (TTM) | US$644.00k |
6.1x
P/S Ratio-0.4x
P/E RatioIs HSDT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSDT income statement (TTM) | |
|---|---|
| Revenue | US$644.00k |
| Cost of Revenue | US$583.00k |
| Gross Profit | US$61.00k |
| Other Expenses | US$8.91m |
| Earnings | -US$8.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.97 |
| Gross Margin | 9.47% |
| Net Profit Margin | -1,374.22% |
| Debt/Equity Ratio | 0% |
How did HSDT perform over the long term?
See historical performance and comparison